Share
Embed
Nebulized Hypertonic Saline for Bronchiolitis in the Emergency Department: A Randomized Clinical Trial
An article by Todd Florin and colleagues.
Article link available:
http://archpedi.jamanetwork.com/article.aspx?articleid=1874076
Please see companion pieces in the same issue:
http://archpedi.jamanetwork.com/article.aspx?articleid=1874075
http://archpedi.jamanetwork.com/article.aspx?articleid=1874078
JAMA Pediatrics
May 27, 2014
Transcript
12 slides
-
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Nebulized
Hypertonic Saline for Bronchiolitis Florin TA, Shaw KN, Kittick M, Yakscoe S, Zorc JJ. Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial. JAMA Pediatr. Published online May 26, 2014. doi:10.1001/jamapediatrics.2013.5306. -
Copyright restrictions may apply • Background – Acute bronchiolitis is
the most frequent lower respiratory infection and most frequent cause for hospitalization in infants. – There are no proven effective therapies for bronchiolitis; nebulized hypertonic saline (HS) has been proposed as a potential therapy. – HS is thought to increase mucociliary clearance by lowering the viscosity of mucus secretions, stimulating cilial beat, and reducing airway edema. – There is conflicting evidence about the role of HS for the treatment of acute bronchiolitis. • Study Objective – To determine whether nebulized 3% HS compared with normal saline (NS) improves respiratory distress in infants with bronchiolitis not responding to a trial of nasal suctioning and nebulized albuterol sulfate in the emergency department (ED). Introduction -
Copyright restrictions may apply • Study Design – Randomized clinical
trial with blinding of investigators, health care providers, and parents. • Setting – A single urban tertiary care pediatric ED during 2 bronchiolitis seasons, from November 1 to April 30 of 2010 and 2011. • Patients – Inclusion: (1) Aged 2 to <24 months, (2) first episode of bronchiolitis (wheezing with signs and symptoms of respiratory distress and upper respiratory infection), (3) Respiratory Distress Assessment Instrument (RDAI) score of 4-15 after albuterol treatment. – Exclusion: (1) History of wheezing or asthma, or bronchodilator therapy before current illness, (2) chronic lung or heart disease, (3) critical illness, (4) inability to receive nebulized medications, (5) non–English- speaking guardians. Methods -
Copyright restrictions may apply • Interventions – 4 mL of
3% HS vs 4 mL of NS. • Outcomes – Primary: Respiratory Assessment Change Score (RACS) at 1 hour after study intervention (RACS = change in RDAI score + standardized change in respiratory rate; decrease in RACS signifies clinical improvement). – Secondary: Vital signs, oxygen saturation, hospitalization, physician clinical impression, parental perception of improvement, adverse events. Respiratory Distress Assessment Instrument (adapted from Lowell et al22) Methods -
Copyright restrictions may apply Results Consolidated Standards for Reporting of
Trials Study Flow Diagram -
Copyright restrictions may apply Results RACS Values 1 Hour After
HS and NS Administration Using a RACS of −3 as a clinically significant improvement, the NS group demonstrated improvement in respiratory status 1 hour after treatment, and the HS group did not substantially improve. -
Copyright restrictions may apply • Difference in RACS at 1
hour after treatment demonstrated significantly less improvement in HS group compared with NS group. • No significant difference in RDAI score. • Greater decrease in respiratory rate from baseline to 1 hour in NS group compared with HS group. • No significant differences in secondary outcomes. Results Outcomes 1 Hour After Saline Administration -
Copyright restrictions may apply Results • No significant difference in
RACS at 2 hours after study intervention between the 2 groups. • During patient follow-up, there were no significant differences between the HS and NS groups in: – Parental perception of study treatment improving their child’s symptoms. – Unscheduled pediatrician visits. – Hospitalization after initially being discharged from the ED. • No adverse events occurred during the study. -
Copyright restrictions may apply Comment • This randomized clinical trial
demonstrated that infants with bronchiolitis with persistent distress after nasal suctioning and a trial of albuterol who received a single dose of nebulized 3% HS in the ED had less improvement in respiratory distress compared with those receiving NS. • Lack of benefit of HS compared with NS in the ED is consistent with findings of prior studies. • These results are in contrast to those of studies examining the use of HS repeatedly over time, which generally show a decreased length of stay in hospitalized infants or improved clinical severity in outpatients. -
Copyright restrictions may apply • Limitations – Single-center study—results may
not be generalizable. – Single dose of 3% HS—relatively low concentration of HS. Results may differ with increasing concentrations or repeated doses. – Intended to separate delivery of albuterol and HS, so primary outcome was measured after peak effect of albuterol; however, it is possible there were residual effects of albuterol at time of assessment. – RACS as short-term outcome; however, ED and primary care providers make disposition and treatment decisions based on short-term outcomes, making this a relevant choice given the practice environment. • Conclusions – HS results in less improvement 1 hour after treatment in the ED compared with NS in infants with bronchiolitis who had persistent distress after albuterol and nasal suctioning. – Administration of a single dose of HS in the acute care setting does not appear to be more effective than NS in improving short-term respiratory distress in bronchiolitis. Comment -
Copyright restrictions may apply • If you have questions, please
contact the corresponding author: – Todd A. Florin, MD, MSCE, Division of Pediatric Emergency Medicine, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, ML 2008, Cincinnati, OH 45229 ([email protected]). Funding/Support • This study was supported by a Young Investigator Award from the Academic Pediatric Association. Conflict of Interest Disclosures • None reported. Contact Information